Evidence map›Paper›PMID 31950290›Full record

ReviewCurrent allergy and asthma reports2020

New Developments in Non-allergen-specific Therapy for the Treatment of Food Allergy.

Andrew Long, Matteo Borro, Vanitha Sampath, R Sharon Chinthrajah

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current allergy and asthma reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Design of allergen-specific inhibitors against shrimp-induced allergic response.The journal of allergy and clinical immunology. Global · 2026
    Article
  2. Observational
  3. The rationale for development of ligelizumab in food allergy.The World Allergy Organization journal · 2022
    Review
  4. Review
  5. [What is the role of allergen immunotherapy in IgE-mediated food allergy?]Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021
    Review
  6. New Insights in Therapy for Food Allergy.Foods (Basel, Switzerland) · 2021
    Review
  7. Update on food allergy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021
    Review
  8. Review
  9. Review
  10. Strategies for Mast Cell Inhibition in Food Allergy.The Yale journal of biology and medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Andrew LongSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Grant Building, S093, 300 Pasteur Dr., Stanford, CA, 94305-5101, USA.
Matteo BorroSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Grant Building, S093, 300 Pasteur Dr., Stanford, CA, 94305-5101, USA.
Vanitha SampathSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Grant Building, S093, 300 Pasteur Dr., Stanford, CA, 94305-5101, USA.
R Sharon ChinthrajahSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Grant Building, S093, 300 Pasteur Dr., Stanford, CA, 94305-5101, USA. schinths@stanford.edu.
Stanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe prevalence of food allergy is increasing. At the current time, there are no approved treatments for food allergy. Major limitations of immunotherapy are long treatment periods (months or years), frequent clinic visits, high costs, increased risk of adverse events during treatment, and lack of durability of desensitization. Additionally, it is allergen-specific, and in those allergic to multiple allergens, the length and cost of treatment are further increased. In this review, we summarize recent developments in novel non-allergen-specific treatments for food allergy. RECENT

findingsA number of monoclonal antibodies that block IgE or specific pro-allergenic cytokines or their receptors have shown promise in clinical trials for food allergy. The insight we have gained through the use of one drug for the treatment of an atopic disease is quickly being translated to other atopic diseases, including food allergy. The future for food allergy treatment with biologics looks bright.

Indexed as

ImmunotherapyAllergensAntibodies, MonoclonalDesensitization, ImmunologicFood HypersensitivityHumansImmunoglobulin EAllergensAntibodies, MonoclonalImmunoglobulin EAtopyBiologicsDupilumabFood allergyImmunotherapyOmalizumab

Identifiers

PMID31950290
OpenAlexW2999132754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.